Gynecologic Oncology

The FDA granted full approval to tisotumab vedotin for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.

Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.

Exploration continues for the use of immunotherapy in patients with mismatch repair–proficient endometrial cancer.

Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Abdulrahman Sinno, MD, discusses the paradigm shift from a histology-based to molecular-based understanding of endometrial cancer and its impact on treatment outcomes.

Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.

Christian Marth, MD, PhD, highlights the prognosis and survival outcomes for patients who are diagnosed with advanced or recurrent endometrial cancer.

Dmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.

Dmitriy Zamarin, MD, PhD, highlights key changes and ongoing research across the endometrial, ovarian, and cervical cancer realms.

Michael Richardson, MD, discusses escalating uterine cancer rates among Asian Americans.

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.

Jay Spiegel, MD, discusses advancing cellular therapies and challenges in gynecologic cancer treatment.

Treatment with XPO1 inhibitors could be effective and warrants further investigation in low-grade serous and clear cell ovarian cancer.

A phase 1b trial is investigating the novel GCN2 kinase activator NXP800 in patients with platinum-resistant, ARID1A-mutated ovarian cancer.

Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.